S. 483In Committee
Responsibility in Drug Advertising Act of 2025
Prohibits direct-to-consumer advertising of newly approved drugs, including on social media, for the first three years after FDA approval with limited FDA exceptions
Plain-English overview
What this bill does
Prohibits direct-to-consumer advertising of newly approved drugs, including on social media, for the first three years after FDA approval with limited FDA exceptions
Key points
- Prohibit new drug advertising
- Authorize extended advertising bans
- Allow FDA waiver requests
Current status
Where it stands
Status
In Committee
Latest action
2025-02-06 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related context
Topics and policy areas
undefinedBroadcasting, cable, digital technologiesDrug safety, medical device, and laboratory regulationHealthInternet, web applications, social mediaMarketing and advertisingPrescription drugs